CAMBRIDGE, Mass.–(BUSINESS WIRE)–Blackstone Life Sciences today announced the launch of Anthos Therapeutics Inc. (“Anthos”), a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients. As part of this launch, Novartis has licensed to Anthos MAA868, an antibody directed at Factor XI and XIa, key components of […]
Financial
Merit Medical Reports Earnings for Fourth Quarter and Year Ended December 31, 2018, Gives 2019 and 2020 Guidance
SOUTH JORDAN, Utah, Feb. 26, 2019 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced revenue of $233.2 million for the quarter ended […]
Itamar Medical to Commence Trading on Nasdaq
CAESAREA, Israel, Feb. 27, 2019 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical device company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that it will list and trade its American Depositary Shares […]
LivaNova Reports Fourth Quarter and Full-Year 2018 Results
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2018. For the fourth quarter of 2018, worldwide sales were $297.0 million, an increase of 6.7 percent on a reported basis and an increase of 9.2 percent on a […]
Anaconda Biomed Expands Leadership Team with Two New Senior Hires
BARCELONA, Spain–(BUSINESS WIRE)–Anaconda Biomed, a medical technology company developing next generation thrombectomy systems for the treatment of ischemic stroke, has announced the appointment of two new senior executives. Lieven Huysse, M.D., has joined the company as chief medical officer (CMO), and Jordi Cardona Vidal will serve as its new manufacturing director. As […]
Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2018. Global revenue in the fourth quarter of 2018 was $34.7 million, a 21.2% decrease from $44.0 million in the […]
Corindus Vascular Robotics Announces Closing of Private Placement for $15 Million
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American:CVRS), a leading developer of precision vascular robotics, today announced the execution of a private placement transaction with a large institutional investor pursuant to which it will sell and issue an aggregate of 10,872,716 shares of its common stock, at […]
BioSig Announces Expansion of Engineering Team
Santa Monica, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company appointed a Senior R&D Engineer and is working on further senior […]
AliveCor Appoints Dr. Jacqueline Shreibati, Chief Medical Officer
MOUNTAIN VIEW, Calif., Feb. 26, 2019 /PRNewswire/ — AliveCor, the leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced Jacqueline Shreibati, MD, MS, FACC, as Chief Medical Officer of the company. In her new role, Dr. Shreibati will lead AliveCor’s medical roadmap, developing innovative products that employ digital intelligence to improve heart care […]
Boston Scientific Completes $4.3 Billion Offering of Senior Notes and Issues Redemption Notice for its 2020 Notes
MARLBOROUGH, Mass., Feb. 25, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million of 3.450% notes due 2024, $850 million of 3.750% notes due 2026, $850 million of 4.000% notes due 2029, $750 millionof 4.550% notes due 2039 and $1.0 billion of 4.700% notes due […]



